Stem cell therapy for central nervous system demyelinating disease.
Recent advances in cell-based therapies for demyelinating central nervous system diseases have demonstrated the ability to restore damaged neuronal architecture and function. Demyelinated axons in patients with multiple sclerosis can spontaneously remyelinate over time; however, the rate and extent at which remyelination occurs is inadequate for complete recovery. Previous attempts aimed at regenerating myelin-forming cells have been successful but limited by the multifocal nature of the lesions and the inability to produce large numbers of myelin-producing cells in culture. Stem cell-based therapy can overcome these limitations to some extent and may prove useful in the future treatment of demyelinating diseases.
Manganas
Louis N
LN
Department of Neurology, Stony Brook University, Stony Brook, NY 11794-8121, USA.
Maletic-Savatic
Mirjana
M
D000818:Animals; D002493:Central Nervous System Diseases / Q000628:therapy*; D002986:Clinical Trials as Topic; D003711:Demyelinating Diseases / Q000628:therapy*; D006801:Humans; D009103:Multiple Sclerosis / Q000628:therapy; D033581:Stem Cell Transplantation / Q000379:methods*; D013234:Stem Cells / Q000502:physiology*